The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Value calls vindicated in August

Tue, 01st Sep 2020 13:00

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

VALUE CALLS VINDICATED IN AUGUST (1159 GMT)

The rising calls to invest in 'value' these last three months have often been met with a
fair whack of scepticism given the awful performance of that investment style in 2020 and the
irresistible surge of Fangs and tech.

Yet, trading in August has pretty much vindicated those who believed that, like they've
often done in the past, rising markets would progressively lift up cheap laggards as the
economic recovery gradually unfolds.

In its dashboard for August, S&P Dow Jones Indices shows how value in Europe outperformed
rival investment styles with a 6.3% monthly rise and a 9.7% jump over the last three months.

Year-to-date though, it's still a 29% fall, which probably means that value ain't causing
that much FOMO so far this year in comparison with say... buying a position in Apple or Tesla!

Here's the S&P Dow Jones Indices Dashboard for Europe:

More on the value theme these last few weeks:

LIVE MARKETS-Value sirens singing the blues

LIVE MARKETS-Actually, talking about value...

LIVE MARKETS-Another value call

LIVE MARKETS-Does U.S. election mean rotation towards value?

LIVE MARKETS-The value value-trap

LIVE MARKETS-Is it value stocks' time?

(Julien Ponthus)

*****

MORE CONCERNS ON SOUTHERN EUROPEAN BANKS (1012 GMT)

Policy response from governments and the European central bank has been strong, the EU
Recovery fund was a major milestone supporting the sector, but most Southern Europe bank shares
are already fully valued, according to some analysts.

Today Europe’s banks are down 1.7%, while the STOXX 600 index is flat with the tech sector
leading gains up 1.5%.

“We would argue the 'value' argument across some names is now is less clear-cut,” a
Jefferies research report says.

The main issue is the economic impact of the second wave of coronavirus infections which has
hit Europe as “the mid-term outlook remains challenged and, despite some pick-up in inflation
expectations, Euribor rates and futures continue to move lower,” it adds.

“While we are broadly aligned with consensus profit expectations in 2022 (on average), we
sit around 10% below consensus on 2022 pre-provision numbers which tempers our enthusiasm.”

Jefferies top picks are Intesa Sanpaolo, Caixabank and Bankia, while the
broker continues to like Unicaja.

(Stefano Rebaudo)

*****

STOXX 600 DOWN? BLAME THE BRITS! (0912 GMT)

There's no need to beat around the bush: if the STOXX 600 is slightly down (-0.1%) this
morning it's all because of London-listed stocks.

Quite striking how the first 32 losers on the pan-European index are ALL London-listed:

As put by AJ Bell analyst Russ Mould, the FTSE "was nursing a hangover after the Bank
Holiday" and was down over 1.3%.

"Not helping the FTSE’s cause was strength in sterling relative to the dollar, a currency
move which impacts the relative weight of the overseas earnings which dominate the index", Mould
added.

Looking at other European bourses, Germany's DAX is doing quite well, up 0.4% and Milan's
FTSE MIB is still in positive territory.

But looking at 2020 so far this year, the underperformance of the FTSE 100 is becoming a key
feature of the COVID-19 vintage.

Here's the FTSE 100 (blue) against the EURO STOXX 50 and the S&P 500:

(Julien Ponthus)

*****

OPENING SNAPSHOT: TECH AND HEALTH CARE SECTORS LEAD GAINS (0728 GMT)

Tech shares, particularly iPhone suppliers, are leading gains in the European stock market
after a press report that Apple Inc has asked suppliers to make at least 75 million 5G
iPhones for later this year, along with new Apple Watch models, a new iPad Air and a smaller
HomePod.

Among Apple suppliers Dialog Semi stocks are up 2.2%, STMicro shares rise
1%, Infineon shares up 1.6%.

The STOXX 600 index is up 0.7% with the tech sector up 1.5%. The healthcare sector is rising
1.2% after AstraZeneca said they could have data to ask U.S. emergency use authorization
or approval of their COVID-19 vaccines in the short term.

Risk sentiment is supported by a strong survey from China, while concerns about pandemic
trajectories continue to weigh. Travel and leisure stocks are the worst performers
sliding 1%, banks continue to lag behind, down 0.2%.

(Stefano Rebaudo)

*****

ON THE RADAR: ASTRAZENECA, APPLE SUPPLIERS, SUEZ

European equities are set to open higher after yesterday’s fall as a strong survey from
China propped up risk sentiment across Europe.

Apple suppliers look poised to gain on report that the world's largest company has
asked suppliers to make at least 75 million 5G iPhones for later this year. Dialog Semi
, STMicro, Infineon and other European chipmakers under spotlight.

Encouraging news on the coronavirus front as AstraZeneca, which is working with
Oxford University researchers, and Pfizer with partner BioNTech, said they
could have data by October to support U.S. emergency use authorization or approval of their
vaccines.

Meanwhile, Sanofi shares could come under pressure after the French pharma major
said its Kevzara drug trial didn't meet main goal in Covid-19 study.

In other key French moves, Suez, which saw its shares rise around 25% after
yesterday’s Veolia offer, said an unsolicited takeover approach carried "great
uncertainties" and it reiterated its confidence as an independent company.

Vivendi and activist fund Amber Capital - the two biggest shareholders in French
company Lagardere - said they would go to court over Lagardere's refusal to hold a
special shareholders meeting.

Roche received approval from the United States Food and Drug Administration for its
Cobas qualitative testing systems to confirm HIV diagnosis.

Apple suppliers

Seadrill proposed to creditors to turn over its stakes in oil services firms
Archer and Seadrill Seabras to redeem its outstanding secured notes.

Shares in Rocket Internet are up 2.6% in premarket trade after the company
announced a delisting plan.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE BLACK BUT WITH VIRUS CONCERNS (0533 GMT)

European stock futures are in the black this morning along with their U.S. peers, but
concerns about the economic impact of the pandemic after the summer break are still in place.

China's factory activity which expanded at the fastest clip in nearly a decade in August,
bolstered by the first increase in new export orders this year, is supporting risk sentiment in
the continent after driving Asian shares in positive territory.

Expectations of long-lasting fiscal and monetary stimulus are also propping up equities, but
pandemic trajectories are expected to be the main investors focus in the fall, at least until a
vaccine is at hand.

(Stefano Rebaudo)

*****

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.